Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider |
|
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.207.294 |
Chemical and physical data | |
Formula | C20H21NO |
Molar mass | 291.394 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
PRC200-SS is an experimental drug of the triple reuptake inhibitor class that was investigated by the Mayo Clinic.[1][2]
Preclinical toxicology studies of PRC200-SS in cynomolgus monkeys showed dose proportional kidney toxicity,[3] precluding any further drug development.
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
|